Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation [0.03%]
MET D1228N 突变是 MET Y1003H 突变非小细胞肺癌患者克唑替尼耐药的一个潜在获得性机制
Jinlian Zhu,Jie Chen,Wei Liu et al.
Jinlian Zhu et al.
Mesenchymal-epithelial transition (MET) gene has been identified as a promising target for treatments. However, different sites of the MET mutation show different effects to MET inhibition. Here, we reported a non-small cell lung cancer (NS...
Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA? [0.03%]
DESTINY-Lung01：HER3-DXd组的中位PFS为5.5个月，与FLAURA-2和MARIPOSA研究结果相比如何？
Zhaohui Liao Arter,Misako Nagasaka
Zhaohui Liao Arter
On December 22, 2023, the US Food and Drug Administration (FDA) approved the biologics license application for patritumab deruxtecan (HER3-DXd) for priority review. This treatment is aimed at adult patients with locally advanced or metastat...
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey [0.03%]
肺癌EGFR活化突变发现二十年来最具影响力的二十篇临床与转化科学论文——编辑部专家共识调查报告
Sai-Hong Ignatius Ou,Xiuning Le,Misako Nagasaka et al.
Sai-Hong Ignatius Ou et al.
The year 2024 is the 20th anniversary of the discovery of activating epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC). Since then, tremendous advances have been made in the treatment of NSCLC based on ...
ATTLAS, IMpower151 and ORIENT-31: Dusting off IMpower150 for Post-Osimertinib in EGFR-Mutated NSCLC? [0.03%]
阿特利、TITAN、IMpower151和ORIENT-31：EGFR突变型NSCLC奥希替尼耐药后的治疗选择——重新审视IMpower150研究
Jii Bum Lee,Sai-Hong Ignatius Ou
Jii Bum Lee
Treatment strategies for post-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy in EGFR-mutant non-small cell lung cancer (NSCLC) is an ongoing challenge. Previously, the IMPRESS trial comparing platinum double...
LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC [0.03%]
LIBRETTO-431：确认塞尔帕替尼对化疗的优越性，以及免疫检查点抑制剂在RET融合阳性晚期NSCLC中缺乏疗效，再次证实NSCLC的独特不吸烟为主分子亚型
Alexandria T M Lee,Sai-Hong Ignatius Ou
Alexandria T M Lee
Selpercatinib, a potent and highly selective RET kinase inhibitor with significant CNS activity, has recently gained US approval for the treatment of NSCLC harboring RET fusions (RET+) based on a large-scale single-arm study. The LIBRETTO-4...
"ACHILLES" Heel No More? Afatinib at 40 Mg Once Daily is Superior to Platinum-Based Chemotherapy in EGFR Uncommon (G719X, S768I, and L861Q) Mutations (ACHILLES/TORG1834) [0.03%]
“阿喀琉斯之踵”不再？艾瑞尼每日一次40毫克优于基于铂的化疗药物治疗少见EGFR突变（G719X，S768I和L861Q）（ACHILLES/TORG1834）
Faustine X Luo,Sai-Hong Ignatius Ou
Faustine X Luo
Afatinib, a second-generation covalent EGFR TKI, has been approved for the treatment of the three "uncommon" EGFR mutations (G719X, S768I, and L861Q) based on one pooled retrospective analysis of three prospective trials (LUX-Lung 2, 3 and ...
HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer [0.03%]
非小细胞肺癌中HMGB1表达水平与免疫治疗疗效相关性研究
Maria González-Cao,Xueting Cai,Jilian Wilhelmina Paulina Bracht et al.
Maria González-Cao et al.
Purpose: High-mobility group box 1 protein (HMGB1) is subject to exportin 1 (XPO1)-dependent nuclear export, and it is involved in functions implicated in resistance to immunotherapy. We investigated whether HMGB1 mRNA ex...
The Butterfly Flies - Practice Changing Results of PAPILLON, First Line Chemotherapy and Amivantamab for the Treatment of NSCLC Patients with EGFR Exon 20 Insertions [0.03%]
蝴蝶展翅——PAPILLON研究：化疗序贯艾伏明塔姆单药治疗EGFR 20号外显子插入突变非小细胞肺癌患者疗效的探索性分析
Dalia Kaakour,Misako Nagasaka
Dalia Kaakour
Epidermal growth factor receptor (EGFR) exon 20 insertions are a rare subtype of EGFR mutations that do not respond to EGFR tyrosine kinase inhibitors developed for sensitizing mutations. In 2021, two drugs, amivantamab and mobocertinib eac...
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting? [0.03%]
玛丽波莎：对于一线治疗，Amivantamab和Lazertinib能否取代Osimertinib？
Danielle Brazel,Misako Nagasaka
Danielle Brazel
Osimertinib is the current first-line treatment for EGFR-mutated NSCLC, however, patients frequently relapse due to acquired resistance mutations. Amivantamab is a bispecific antibody against EGFR and MET alterations. Lazertinib is a tyrosi...
Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study [0.03%]
阿帕替尼联合PD-1抗体治疗免疫经治晚期非小细胞肺癌的疗效和安全性：回顾性探索研究
Xue-Jun Dou,Run-Yang Ma,De-Wang Ren et al.
Xue-Jun Dou et al.
Objective: This study aimed to investigate the effectiveness and tolerability of anlotinib plus PD-1 blockades in patients with previously immunotherapy treated advanced non-small-cell lung cancer (NSCLC). ...